Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambisome in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis
NCT02273661Phase 2Completed
- Sponsor
- CHU de Poitiers
- Start
- Nov 2014
- Primary completion
- Jun 2019
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of liposomal amphotericin b in allergic bronchopulmonary aspergillosis (ABPA) (2 arms), sponsored by CHU de Poitiers. Primary endpoint: Occurrence of first severe clinical exacerbation at 24 months. Started Nov 2014; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT02273661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273661.